DURHAM, N.C., March 17, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), recently announced positive topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), an investigational therapy underdevelopment for the treatment of microcystic lymphatic malformations (microcystic LMs).